Table 2– Characteristics of the European Community and Respiratory Health Survey (ECRHS)II population and probability of individuals presenting the characteristics, by inclusion in each of the four phenotypes identified by the latent class analysis

	All subjects	Phenotype A	Phenotype B	Phenotype C	Phenotype D
Subjects n (%)	1895 (100.0)	685 (36.1)	363 (19.2)	548 (28.9)	299 (15.8)
Age ≥40 yrs	0.60	0.50	0.76	0.55	0.73
Male sex	0.41	0.49	0.25	0.46	0.33
Age at asthma onset yrs
≤4	0.16	0.20	0.04	0.16	0.20
4–16	0.30	0.40	0.12	0.38	0.17
>16	0.54	0.40	0.84	0.46	0.63
Woken by coughing^#	0.45	0.45	0.79	0.26	0.35
Asthma symptom score^#
0 symptom	0.24	0.03	0.02	0.52	0.50
1–2 symptoms	0.40	0.38	0.30	0.45	0.48
≥3 symptoms	0.36	0.59	0.67	0.03	0.02
Chronic cough or phlegm	0.22	0.24	0.46	0.09	0.17
Asthma attack^#	0.43	0.75	0.73	0.06	0.04
Exacerbation^#	0.10	0.17	0.22	0.00	0.01
Asthma treatment^¶
No treatment	0.44	0.08	0.20	0.75	0.79
Other than daily ICS	0.39	0.64	0.49	0.19	0.18
Daily ICS	0.17	0.28	0.31	0.06	0.03
Eczema	0.57	0.63	0.44	0.59	0.58
Rhinitis	0.65	0.78	0.54	0.75	0.31
Atopy	0.64	0.96	0.05	0.98	0.00
IgE ≥100 IU·mL⁻¹	0.46	0.74	0.15	0.50	0.11
FEV₁ <80% pred	0.13	0.19	0.18	0.05	0.08
AHR⁺	0.48	0.76	0.44	0.36	0.20

Data are presented as the probability of individuals presenting the characteristics, unless otherwise stated. ICS: inhaled corticocosteroid; Ig: immunoglobulin; FEV₁: forced expiratory volume in 1 s; % pred: % predicted; AHR: airway hyperresponsiveness. ^#: in the previous 12 months; ^¶: in the previous 3 months; ⁺: provocative dose causing a 20% fall in FEV₁ ≤1 mg methacholine.